Johnson & Johnson (NYSE: JNJ) reported its third quarter 2025 earnings results today.
Reported sales increased 6.8% year-over-year to $24 billion. Operational sales were up 5.4%.
GAAP net earnings rose 91% to $5.2 billion, or $2.12 per share, compared to last year. Adjusted EPS grew 16% to $2.80.
Revenue and earnings beat estimates.
The company raised its sales guidance for the full year of 2025 and now expects reported sales to be $93.5-93.9 billion. It reaffirmed its guidance for adjusted EPS, which is expected to be $10.80-10.90.
In a separate release, JNJ announced its intent to separate its Orthopaedics business to improve strategic focus and drive shareholder value. The transaction would create a standalone orthopaedics business named DePuy Synthes. The company has appointed Namal Nawana as Worldwide President, DePuy Synthes, effective immediately. It expects to complete this transaction within 18 to 24 months, based on certain conditions.
JNJ also declared a cash dividend of $1.30 per common share for the fourth quarter of 2025, payable on December 9, 2025 to shareholders of record as of November 25, 2025.